|
CA672478A
(en)
|
|
1963-10-15 |
Heim Roger |
Psilocybin and psilocin
|
|
LU36879A1
(ko)
|
1958-02-21 |
|
|
|
|
GB911946A
(en)
|
1958-02-21 |
1962-12-05 |
Sandoz Ltd |
Psilocybin and psilocin and processes for their preparation
|
|
NL243249A
(ko)
|
1958-09-12 |
|
|
|
|
US3075992A
(en)
|
1958-09-12 |
1963-01-29 |
Sandoz Ltd |
Esters of indoles
|
|
US3192111A
(en)
|
1959-02-16 |
1965-06-29 |
Sandoz Ltd |
Method of inducing therapeutic tranquilization with psilocybin and psilocin
|
|
IE24138L
(en)
|
1959-02-18 |
1959-08-21 |
Sandoz Ag |
Psilocybin and psilocin
|
|
JPS5576859A
(en)
|
1978-12-01 |
1980-06-10 |
Fujimoto Seiyaku Kk |
Novel preparation of 4-hydroxyindole
|
|
JPS5728046A
(en)
|
1980-07-28 |
1982-02-15 |
Nissan Chem Ind Ltd |
Preparation of 4-substituted indole
|
|
US4499096A
(en)
|
1983-11-18 |
1985-02-12 |
Lotsof Howard S |
Rapid method for interrupting the narcotic addiction syndrome
|
|
EP0152379A3
(de)
|
1984-02-15 |
1986-10-29 |
Ciba-Geigy Ag |
Verfahren zur Herstellung von pharmazeutischen Zusammensetzungen enthaltend unilamellare Liposomen
|
|
US4721612A
(en)
|
1984-04-12 |
1988-01-26 |
The Liposome Company, Inc. |
Steroidal liposomes
|
|
IL76591A0
(en)
|
1984-10-05 |
1986-02-28 |
Bioferon Biochem Substanz |
Pharmaceutical compositions containing ifn-ypsilon and processes for the preparation thereof
|
|
US5785989A
(en)
|
1985-05-01 |
1998-07-28 |
University Utah Research Foundation |
Compositions and methods of manufacturing of oral dissolvable medicaments
|
|
US4587243A
(en)
|
1985-07-15 |
1986-05-06 |
Lotsof Howard S |
Rapid method for interrupting the cocaine and amphetamine abuse syndrome
|
|
DE218479T1
(de)
|
1985-10-04 |
1992-03-19 |
South African Inventions Development Corp., Pretoria, Transvaal, Za |
Reagens und verfahren.
|
|
US5725871A
(en)
|
1989-08-18 |
1998-03-10 |
Danbiosyst Uk Limited |
Drug delivery compositions comprising lysophosphoglycerolipid
|
|
DE68928415T2
(de)
|
1989-09-05 |
1998-02-26 |
Univ Utah Research Inst |
Verfahren und zusammensetzungen zur verabreichung von lipophilen heilmitteln in einer dosierung nach der gewünschten wirkung
|
|
US5629307A
(en)
|
1989-10-20 |
1997-05-13 |
Olney; John W. |
Use of ibogaine in reducing excitotoxic brain damage
|
|
US5935925A
(en)
|
1990-05-08 |
1999-08-10 |
Synaptic Pharmaceutical Corporation |
Methods of treating migraine and compounds useful for such methods
|
|
US5626863A
(en)
|
1992-02-28 |
1997-05-06 |
Board Of Regents, The University Of Texas System |
Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
|
|
ES2193132T3
(es)
|
1990-10-19 |
2003-11-01 |
Univ New York |
Procedimiento para transplantar celulas en el cerebro y utilizaciones terapeuticas del mismo.
|
|
US5827819A
(en)
|
1990-11-01 |
1998-10-27 |
Oregon Health Sciences University |
Covalent polar lipid conjugates with neurologically active compounds for targeting
|
|
FR2675504B1
(fr)
|
1991-04-16 |
1995-01-27 |
Delalande Sa |
Derives d'aryl-3 oxazolidinone, leur procede de preparation et leur application en therapeutique.
|
|
US5468486A
(en)
|
1992-01-21 |
1995-11-21 |
The University Of Tennessee Research Corporation |
Vaccine containing a protein alkaloid conjugate for the treatment of fescue toxicosis
|
|
EP0566135A1
(en)
|
1992-04-17 |
1993-10-20 |
Takeda Chemical Industries, Ltd. |
Transmucosal composition comprising a peptide and a cytidine derivative
|
|
US5871710A
(en)
|
1992-09-04 |
1999-02-16 |
The General Hospital Corporation |
Graft co-polymer adducts of platinum (II) compounds
|
|
US5573776A
(en)
|
1992-12-02 |
1996-11-12 |
Alza Corporation |
Oral osmotic device with hydrogel driving member
|
|
PL304893A1
(en)
|
1992-12-24 |
1995-01-09 |
Erba Carlo Spa |
Serotoninergic derivatives of ergoline
|
|
ES2068762B1
(es)
|
1993-07-21 |
1995-12-01 |
Lipotec Sa |
Un nuevo preparado farmaceutico para mejorar la biodisponibilidad de drogas de dificil absorcion y procedimiento para su obtencion.
|
|
US5545617A
(en)
|
1993-11-12 |
1996-08-13 |
The Schepens Eye Research Institute, Inc. |
Therapeutic regulation of abnormal conjunctival goblet cell mucous secretion
|
|
US20060019963A1
(en)
|
1994-06-17 |
2006-01-26 |
Smithkline Beecham Corporation |
Compounds
|
|
WO1996003127A1
(en)
|
1994-07-25 |
1996-02-08 |
Nda International, Inc. |
A method of treating chemical dependency in mammals and a composition therefor
|
|
US5874477A
(en)
|
1994-08-12 |
1999-02-23 |
The University Of Hawaii |
Method of treatment for malaria utilizing serotonin receptor ligands
|
|
US5696125A
(en)
|
1995-02-24 |
1997-12-09 |
Research Foundation Of The State University Of New York |
Substance abuse-induced hemorrhagic stoke in an animal model
|
|
US5643586A
(en)
|
1995-04-27 |
1997-07-01 |
Perricone; Nicholas V. |
Topical compositions and methods for treatment of skin damage and aging using catecholamines and related compounds
|
|
CN1156961A
(zh)
|
1995-06-09 |
1997-08-13 |
欧罗赛铁克股份有限公司 |
产生长效局部麻醉的制剂和方法
|
|
US5879690A
(en)
|
1995-09-07 |
1999-03-09 |
Perricone; Nicholas V. |
Topical administration of catecholamines and related compounds to subcutaneous muscle tissue using percutaneous penetration enhancers
|
|
DE19542281C2
(de)
|
1995-11-14 |
1997-12-04 |
Boehringer Ingelheim Kg |
Verwendung von Epinastin für die Behandlung der Migräne
|
|
FR2744361B1
(fr)
|
1996-02-07 |
1998-02-27 |
Rhone Poulenc Rorer Sa |
Application de derives de pyrrolidine a la preparation de medicaments destines au traitement de l'abus de drogues ou de substances donnant lieu a des pharmacomanies ou a un usage excessif
|
|
FR2744363B1
(fr)
|
1996-02-07 |
1998-02-27 |
Rhone Poulenc Rorer Sa |
Application de derives de thiazolidine a la preparation de medicaments destines au traitement de l'abus de drogues ou de substances donnant lieu a des pharmacomanies ou a un usage excessif
|
|
FR2744364B1
(fr)
|
1996-02-07 |
1998-02-27 |
Rhone Poulenc Rorer Sa |
Application d'ureidoacetamides a la preparation de medicaments destines au traitement de l'abus de drogues ou de substances donnant lieu a des pharmacomanies ou a un usage excessif
|
|
FR2744362B1
(fr)
|
1996-02-07 |
1998-02-27 |
Rhone Poulenc Rorer Sa |
Application de derives de pyrrolidine a la preparation de medicaments destines au traitement de l'abus de drogues ou de substances donnant lieu a des pharmacomanies ou a un usage excessif
|
|
JP2000507544A
(ja)
|
1996-03-25 |
2000-06-20 |
イーライ・リリー・アンド・カンパニー |
痛みの治療方法
|
|
TW448171B
(en)
|
1996-06-06 |
2001-08-01 |
Yamanouchi Pharma Co Ltd |
Imidazole-substituted quinoxalinedione derivatives
|
|
AU3290397A
(en)
|
1996-06-10 |
1998-01-07 |
Depomed, Inc. |
Gastric-retentive oral controlled drug delivery system with enhanced retention properties
|
|
US5914129A
(en)
|
1996-07-23 |
1999-06-22 |
Mauskop; Alexander |
Analgesic composition for treatment of migraine headaches
|
|
US5902815A
(en)
|
1996-09-03 |
1999-05-11 |
Washington University |
Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
|
|
US5958919A
(en)
|
1996-09-20 |
1999-09-28 |
Washington University |
Treatment of presymptomatic alzheimer's disease to prevent neuronal degeneration
|
|
US5891885A
(en)
|
1996-10-09 |
1999-04-06 |
Algos Pharmaceutical Corporation |
Method for treating migraine
|
|
US6479074B2
(en)
|
1996-10-24 |
2002-11-12 |
Pharmaceutical Applications Associates Llc |
Methods and transdermal compositions for pain relief
|
|
US5804592A
(en)
|
1997-05-30 |
1998-09-08 |
Unimed Pharmaceuticals, Inc. |
Method for improving disturbed behavior and elevating mood in humans
|
|
IL132784A
(en)
|
1997-05-07 |
2004-07-25 |
Unimed Pharmaceutical Inc |
Pharmaceutical compositions containing dronabinol
|
|
AU8261098A
(en)
|
1997-06-24 |
1999-01-04 |
University Of Wyoming |
Method and apparatus for detection of a controlled substance
|
|
GB9715082D0
(en)
|
1997-07-17 |
1997-09-24 |
Scherer Ltd R P |
Treatment of attention deficit hyperactivity disorder and narcolepsy
|
|
US20010004644A1
(en)
|
1997-07-21 |
2001-06-21 |
Levin Bruce H. |
Compositions, kits, apparatus, and methods for inhibiting cephalic inflammation
|
|
US7799337B2
(en)
|
1997-07-21 |
2010-09-21 |
Levin Bruce H |
Method for directed intranasal administration of a composition
|
|
WO1999009828A1
(en)
|
1997-08-25 |
1999-03-04 |
Pentech Pharmaceuticals, Inc. |
Method for amelioration of social phobia
|
|
ES2395268T3
(es)
|
1997-09-04 |
2013-02-11 |
Demerx, Inc. |
Noribogaína para el tratamiento del dolor y la drogadicción
|
|
US7220737B1
(en)
|
1997-09-04 |
2007-05-22 |
Novoneuron, Inc |
Noribogaine in the treatment of pain and drug addiction
|
|
DE19738855C2
(de)
|
1997-09-05 |
2001-01-04 |
Lohmann Therapie Syst Lts |
Transdermales therapeutisches System mit haftklebender Reservoirschicht und unidirektional elastischer Rückschicht
|
|
US20030077227A1
(en)
|
1997-10-01 |
2003-04-24 |
Dugger Harry A. |
Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
|
|
US6228864B1
(en)
|
1997-10-28 |
2001-05-08 |
Vivus, Inc. |
Administration of 5-HT receptor agonists and antagonists, to treat premature ejaculation
|
|
US5922341A
(en)
|
1997-10-28 |
1999-07-13 |
Vivus, Incorporated |
Local administration of pharmacologically active agents to treat premature ejaculation
|
|
US6037346A
(en)
|
1997-10-28 |
2000-03-14 |
Vivus, Inc. |
Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
|
|
JP2001520999A
(ja)
|
1997-10-28 |
2001-11-06 |
アシビ， エルエルシー |
女性の性的機能不全の処置
|
|
ITTO980264A1
(it)
|
1998-03-26 |
1999-09-26 |
Silvio Rossi |
Applicazione di un estratto basico non quaternario della peschiera fuchsiaefolia ad attivita' antimalarica
|
|
CA2334550A1
(en)
|
1998-06-22 |
1999-12-29 |
Queen's University At Kingston |
Method and compositions for the treatment or amelioration of female sexual dysfunction
|
|
WO2000003746A2
(en)
|
1998-07-14 |
2000-01-27 |
The Brigham And Women's Hospital, Inc. |
Upregulation of type iii endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
|
|
WO2000003679A2
(en)
|
1998-07-14 |
2000-01-27 |
Adams Food Ltd. |
Nutritionally active composition for hardening fingernails
|
|
WO2000003701A1
(en)
|
1998-07-16 |
2000-01-27 |
Massachusetts Institute Of Technology |
Composition for treatment of stress
|
|
MXPA01001180A
(es)
|
1998-07-31 |
2002-04-24 |
Vela Pharmaceuticals Inc |
Metodos y composiciones para el tratamiento y la prevencion de abuso de sustancias empleando moclobemida.
|
|
KR20010073153A
(ko)
|
1998-09-18 |
2001-07-31 |
제임스 에이. 아노 |
녹내장 치료용의 세로토닌성 5ｈｔ2 작용제
|
|
US20060025387A1
(en)
|
1998-12-23 |
2006-02-02 |
Cytoscan Sciences Llc |
Compositions and methods for the treatment of disorders of the central and peripheral nervous systems
|
|
US6962717B1
(en)
|
1999-01-29 |
2005-11-08 |
Disphar International B.V. |
Pharmaceutical compositions
|
|
WO2000050020A2
(en)
|
1999-02-24 |
2000-08-31 |
University Of Cincinnati |
Use of sulfamate derivatives for treating impulse control disorders
|
|
CA2368187A1
(en)
|
1999-03-19 |
2000-09-28 |
Brigham And Women's Hospital, Inc. |
Upregulation of type iii endothelial cell nitric oxide synthase by hmg-coa reductase inhibitors
|
|
EP1165054A4
(en)
|
1999-04-06 |
2005-02-09 |
Pharmaquest Ltd |
PHARMACEUTICAL DOSAGE FORM FOR INTERMITTENT DELIVERY OF METHYLPHENIDATE
|
|
US6383471B1
(en)
|
1999-04-06 |
2002-05-07 |
Lipocine, Inc. |
Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
|
|
TR200102876T2
(tr)
|
1999-04-07 |
2006-12-21 |
Pfizer Products Inc. |
Bileşim tedavilerinde CYP2D6 önleyicilerinin kullanılması.
|
|
US6126924A
(en)
|
1999-05-27 |
2000-10-03 |
Scales-Medeiros; Virginia A. |
Light responsive self-tanning products and methods for use
|
|
US6495498B2
(en)
|
1999-05-27 |
2002-12-17 |
Johnson & Johnson Consumer Companies, Inc. |
Detergent compositions with enhanced depositing, conditioning and softness capabilities
|
|
US6489341B1
(en)
|
1999-06-02 |
2002-12-03 |
Sepracor Inc. |
Methods for the treatment of neuroleptic and related disorders using sertindole derivatives
|
|
US20080103179A1
(en)
|
2006-10-27 |
2008-05-01 |
Tam Peter Y |
Combination Therapy
|
|
US6500459B1
(en)
|
1999-07-21 |
2002-12-31 |
Harinderpal Chhabra |
Controlled onset and sustained release dosage forms and the preparation thereof
|
|
WO2001013935A2
(en)
|
1999-08-23 |
2001-03-01 |
The Administrators Of The Tulane Educational Fund |
Modulation of the blood-brain barrier transporter for leptin
|
|
US6204245B1
(en)
|
1999-09-17 |
2001-03-20 |
The Regents Of The University Of California |
Treatment of narcolepsy with immunosuppressants
|
|
AU8003800A
(en)
|
1999-10-08 |
2001-04-23 |
Joyce Corinne Bechthold |
Methods and compositions for treating neurobehavioral disorders
|
|
ES2162746B1
(es)
|
1999-10-21 |
2003-02-16 |
Lipotec Sa |
Microcapsulas para la estabilizacion de productos cosmeticos, farmaceuticos o de alimentacion.
|
|
US6693135B2
(en)
|
2000-01-10 |
2004-02-17 |
Nexmed (Holdings) Incorporated |
Prostaglandin compositions and methods of treatment for male erectile dysfunction
|
|
AU775516B2
(en)
|
2000-01-18 |
2004-08-05 |
Trustees Of The University Of Pennsylvania, The |
Ocular growth and nicotinic antagonists
|
|
US20030096831A1
(en)
|
2000-01-18 |
2003-05-22 |
Stone Richard A. |
Ocular growth and nicotinic antagonists
|
|
FR2804603B1
(fr)
|
2000-02-04 |
2004-01-23 |
Rhodia Chimie Sa |
Procede continu pour formuler sous forme de granules une ou plusieurs matieres actives pharmaceutiques
|
|
US20020015730A1
(en)
|
2000-03-09 |
2002-02-07 |
Torsten Hoffmann |
Pharmaceutical formulations and method for making
|
|
AU2001243369A1
(en)
|
2000-03-14 |
2001-09-24 |
Massachusetts Institute Of Technology |
Composition and method to treat weight gain and obesity attributable to psychotropic drugs
|
|
DE10014588A1
(de)
|
2000-03-27 |
2001-10-04 |
Basf Ag |
Wirkstoffhaltige Schwimmformen enthaltend Polyvinylacetat und Polyvinylpyrrolidon, deren Verwendung und Herstellung
|
|
JP2003528635A
(ja)
|
2000-03-27 |
2003-09-30 |
ピーイー コーポレーション （エヌワイ） |
単離ヒトｇタンパク質共役受容体、ヒトｇｐｃｒタンパク質をコード化している核酸分子、及びそれらの使用
|
|
US6380176B2
(en)
|
2000-03-28 |
2002-04-30 |
Ajinomoto Co., Inc. |
Method for inhibiting non-intentional behavior with a running neuron inhibitory substance
|
|
DE10018834A1
(de)
|
2000-04-15 |
2001-10-25 |
Lohmann Therapie Syst Lts |
Transdermale oder transmucosale Darreichungsformen mit einer nicotinhaltigen Wirkstoffkombination zur Raucherentwöhnung
|
|
AU6106801A
(en)
|
2000-04-28 |
2001-11-12 |
Gary W. Neal |
Trans-clitoral administration of therapy
|
|
AU2001259671B2
(en)
|
2000-05-10 |
2004-06-24 |
Rtp Pharma Inc. |
Media milling
|
|
US20020044962A1
(en)
|
2000-06-06 |
2002-04-18 |
Cherukuri S. Rao |
Encapsulation products for controlled or extended release
|
|
US20070059367A1
(en)
|
2000-06-06 |
2007-03-15 |
Cherukuri S R |
Drug Delivery System and Associated Methods
|
|
US20020019421A1
(en)
|
2000-07-05 |
2002-02-14 |
Roni Biberman |
Compositions and therapy for substance addiction
|
|
DK1476171T3
(da)
|
2000-07-19 |
2011-01-10 |
Univ Northwest |
Transport af nukleinsyresubstanser
|
|
WO2002024865A2
(en)
|
2000-09-19 |
2002-03-28 |
Microbia, Inc. |
Modulation of secondary metabolite production by zinc binuclear cluster proteins
|
|
US9399050B2
(en)
|
2000-10-04 |
2016-07-26 |
Paul Edward Stamets |
Controlling insects and arthropods using preconidial mycelium and extracts of preconidial mycelium from entomopathogenic fungi
|
|
US9474776B2
(en)
|
2000-10-04 |
2016-10-25 |
Paul Edward Stamets |
Integrative fungal solutions for protecting bees
|
|
US20070099999A1
(en)
|
2000-11-01 |
2007-05-03 |
Epstein Mel H |
Methods of treating depression
|
|
US20030119884A1
(en)
|
2000-11-01 |
2003-06-26 |
Epstein Mel H. |
Methods and compositions for regulating memory consolidation
|
|
AR031473A1
(es)
|
2000-11-20 |
2003-09-24 |
Lundbeck & Co As H |
Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide
|
|
CA2359812C
(en)
|
2000-11-20 |
2004-02-10 |
The Procter & Gamble Company |
Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
|
|
US6495154B1
(en)
|
2000-11-21 |
2002-12-17 |
Vivus Inc. |
On demand administration of clomipramine and salts thereof to treat premature ejaculation
|
|
IL139975A0
(en)
|
2000-11-29 |
2002-02-10 |
Univ Ramot |
Anti proliferative drugs
|
|
EE200300249A
(et)
|
2000-11-30 |
2003-10-15 |
Pfizer Products Inc. |
GABA agonistide ja aldoosreduktaasi inhibiitoritekombinatsioon
|
|
PL365927A1
(en)
|
2000-11-30 |
2005-01-10 |
Pfizer Products Inc. |
Combination of gaba agonists and sorbitol dehydrogenase inhibitors
|
|
US20050176790A1
(en)
|
2001-02-28 |
2005-08-11 |
Johannes Bartholomaus |
Pharmaceutical salts
|
|
US20020137785A1
(en)
|
2001-03-26 |
2002-09-26 |
George Kindness |
Inflammatory mechanism modulator composition and methods with anti-asthmatic properties
|
|
US20050096396A1
(en)
|
2002-03-28 |
2005-05-05 |
Emory University |
Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
|
|
US6979447B2
(en)
|
2001-03-30 |
2005-12-27 |
Philadelphia Health And Education Corporation |
Immunomodulation and effect on cell processes relating to serotonin family receptors
|
|
US6632217B2
(en)
|
2001-04-19 |
2003-10-14 |
Microsolutions, Inc. |
Implantable osmotic pump
|
|
EP1423114A4
(en)
|
2001-05-04 |
2006-05-17 |
Merck & Co Inc |
METHOD AND COMPOSITIONS FOR TREATING MIGRAINE
|
|
US20030051728A1
(en)
|
2001-06-05 |
2003-03-20 |
Lloyd Peter M. |
Method and device for delivering a physiologically active compound
|
|
US20040023952A1
(en)
|
2001-06-20 |
2004-02-05 |
Leventhal Audie G. |
Enhanced brain function by gaba-ergic stimulation
|
|
AU2002332942A1
(en)
|
2001-08-20 |
2003-03-03 |
Greiner Bio-One Gmbh |
Device and method for determining an analyte
|
|
US6541043B2
(en)
|
2001-08-28 |
2003-04-01 |
Dexgen Pharmaceuticals, Inc. |
Method and synergistic composition for treating attention deficit/hyperactivity disorder
|
|
US20030099711A1
(en)
|
2001-08-29 |
2003-05-29 |
David Meadows |
Sustained release preparations
|
|
AU2002339224B2
(en)
|
2001-09-14 |
2008-10-09 |
Kuros Us Llc |
Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
|
|
JP4360906B2
(ja)
|
2001-09-14 |
2009-11-11 |
サイトス バイオテクノロジー アーゲー |
ウィルス様粒子によって誘導される免疫応答を高めるための、抗原提示細胞のインビボでの活性化
|
|
WO2003026564A2
(en)
|
2001-09-27 |
2003-04-03 |
Pharmacia Ab |
Pharmaceutical compositions for the treatment of urinary disorders
|
|
US7544681B2
(en)
|
2001-09-27 |
2009-06-09 |
Ramot At Tel Aviv University Ltd. |
Conjugated psychotropic drugs and uses thereof
|
|
US6592901B2
(en)
|
2001-10-15 |
2003-07-15 |
Hercules Incorporated |
Highly compressible ethylcellulose for tableting
|
|
US20060264508A1
(en)
|
2001-10-16 |
2006-11-23 |
Stone Richard A |
Modulation of ocular growth and myopia by gaba drugs
|
|
US20030082225A1
(en)
|
2001-10-19 |
2003-05-01 |
Mason Paul Arthur |
Sterile, breathable patch for treating wound pain
|
|
US7045543B2
(en)
|
2001-11-05 |
2006-05-16 |
Enzrel Inc. |
Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites
|
|
EP1453468A4
(en)
|
2001-11-09 |
2005-11-23 |
Chiron Corp |
METHOD OF VACCINATION OF A HUMAN PATIENT TO PREVENT METASTATIC TUMORS
|
|
GB0127832D0
(en)
|
2001-11-20 |
2002-01-09 |
Jagotec Ag |
Method for the preparation of pharmaceutical nanosuspensions
|
|
EP1450801A4
(en)
|
2001-11-27 |
2010-10-27 |
Merck Sharp & Dohme |
2-AMINOQUINOLINE COMPOUNDS
|
|
EP1451156A4
(en)
|
2001-11-27 |
2005-05-25 |
Merck & Co Inc |
4-AMINOQUINOLINE COMPOUNDS
|
|
AU2002219964A1
(en)
|
2001-11-29 |
2003-06-17 |
Penwest Pharmaceutical Company |
Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose
|
|
US7241797B2
(en)
|
2002-01-23 |
2007-07-10 |
University Of Cincinnati |
Method of increasing milk production
|
|
US20030171435A1
(en)
|
2002-01-23 |
2003-09-11 |
Drug Abuse Sciences, Inc. |
New amphetamine derivatives, antibodies against them and pharmaceutical compositions containing them
|
|
EP1480624B1
(en)
|
2002-02-07 |
2006-11-29 |
Pharmacia Corporation |
Pharmaceutical tablet
|
|
NZ534340A
(en)
|
2002-02-07 |
2006-04-28 |
Pharmacia Corp |
Pharmaceutical dosage form for mucosal delivery
|
|
US20030153552A1
(en)
|
2002-02-14 |
2003-08-14 |
Mash Deborah C. |
Method of treating chemical dependency in mammals and a composition therefor
|
|
WO2006121552A2
(en)
|
2005-04-08 |
2006-11-16 |
New River Pharmaceuticals Inc. |
Abuse-resistant amphetamine prodrugs
|
|
US7700561B2
(en)
|
2002-02-22 |
2010-04-20 |
Shire Llc |
Abuse-resistant amphetamine prodrugs
|
|
DE10208335A1
(de)
|
2002-02-27 |
2003-09-04 |
Roehm Gmbh |
Arzneiform und Verfahren zu ihrer Herstellung
|
|
US20030199439A1
(en)
|
2002-04-22 |
2003-10-23 |
Simon David Lew |
Compositions of alpha3beta4 receptor antagonists and opioid agonist analgesics
|
|
CA2483093A1
(en)
|
2002-04-24 |
2003-11-06 |
Cypress Bioscience, Inc. |
Use of milnacipran or a pharmaceutically acceptable salt thereof for treating chronic low back pain
|
|
WO2003092676A1
(en)
|
2002-04-29 |
2003-11-13 |
The General Hospital Corporation |
Compositions and methods for preventing abuse of orally administered medications
|
|
AUPS317102A0
(en)
|
2002-06-25 |
2002-07-18 |
Drug Delivery Solutions Pty Ltd |
Transdermal aerosol compositions
|
|
US20040077540A1
(en)
|
2002-06-28 |
2004-04-22 |
Nastech Pharmaceutical Company Inc. |
Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds
|
|
US20040006043A1
(en)
|
2002-07-02 |
2004-01-08 |
Ramot University Authority For Applied Research & Industrial Development Ltd. |
Methods, pharmaceutical compositions and pharmaceutical kits for enhancing the therapeutic efficiency of cancer chemotherapeutic agents
|
|
US10738268B2
(en)
|
2016-08-21 |
2020-08-11 |
Insectergy, Llc |
Cannabis nanoemulsion methods
|
|
US20050148673A1
(en)
|
2002-07-11 |
2005-07-07 |
Harbut Ronald E. |
Prolonged administration of NMDA antagonist and safener drug to alter neuropathic pain condition
|
|
AU2003246690B2
(en)
|
2002-07-17 |
2010-03-11 |
Cytos Biotechnology Ag |
Molecular antigen arrays using a virus like particle derived from the AP205 coat protein
|
|
US6932971B2
(en)
|
2002-07-18 |
2005-08-23 |
Cytos Biotechnology Ag |
Hapten-carrier conjugates and uses thereof
|
|
US7838034B2
(en)
|
2002-07-30 |
2010-11-23 |
Grunenthal Gmbh |
Intravenous pharmaceutical form of administration
|
|
JPWO2004014429A1
(ja)
|
2002-08-09 |
2005-12-02 |
三菱ウェルファーマ株式会社 |
精神疾患発症脆弱性制御剤
|
|
US20030114512A1
(en)
|
2002-09-09 |
2003-06-19 |
Collier Robert J |
Compounds with 5-ht2 and 5-ht1a agonist activity for treating glaucoma
|
|
WO2004025268A2
(en)
|
2002-09-13 |
2004-03-25 |
Carnegie Mellon University |
Optical biosensors and methods of use thereof
|
|
EP1542665A1
(en)
|
2002-09-19 |
2005-06-22 |
Merck & Co., Inc. |
Method for treating depression and/or anxiety
|
|
US6913768B2
(en)
|
2002-09-24 |
2005-07-05 |
Shire Laboratories, Inc. |
Sustained release delivery of amphetamine salts
|
|
DE10244504A1
(de)
|
2002-09-25 |
2004-04-08 |
Capsulution Nanoscience Ag |
Schnellfreisetzende Darreichungsform mit schwerlöslichem Wirkstoff
|
|
MXPA05003744A
(es)
|
2002-10-11 |
2005-09-20 |
Idea Ag |
Agregado de deformabilidad aumentada, que comprende al menos tres anfipatos, para un transporte mejorado a traves de barreras semi-permeables y para la aplicacion de farmacos no invasivos en vivo, en especial a traves de la piel.
|
|
AU2003304211A1
(en)
|
2002-10-30 |
2005-01-04 |
The Regents Of The University Of California |
Direct micro-patterning of lipid bilayers using uv light and selected uses thereof
|
|
DE10250944B9
(de)
|
2002-10-31 |
2004-09-16 |
Cell Center Cologne Gmbh |
Verwendung eines Stifts zur Applikation von Pflege- oder Wirkstoffen in die Nase
|
|
US7670627B2
(en)
|
2002-12-09 |
2010-03-02 |
Salvona Ip Llc |
pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
|
|
CA2511606A1
(en)
|
2002-12-24 |
2004-07-15 |
Neurochem (International) Limited |
Therapeutic formulations for the treatment of beta-amyloid related diseases
|
|
US7601740B2
(en)
|
2003-01-16 |
2009-10-13 |
Acadia Pharmaceuticals, Inc. |
Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
|
|
US20040224942A1
(en)
|
2003-01-23 |
2004-11-11 |
Weiner David M. |
Use of N-desmethylclozapine to treat human neuropsychiatric disease
|
|
US20040186155A1
(en)
|
2003-01-30 |
2004-09-23 |
Dayno Jeffrey Marc |
Combination therapy for the treatment or prevention of migraine
|
|
EP1603548A4
(en)
|
2003-02-05 |
2007-10-10 |
Myriad Genetics Inc |
COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS
|
|
US20040214215A1
(en)
|
2003-03-07 |
2004-10-28 |
Yu Ruey J. |
Bioavailability and improved delivery of alkaline pharmaceutical drugs
|
|
DK1610796T3
(da)
|
2003-03-17 |
2014-07-21 |
Neurohealing Pharmaceuticals Inc |
Højpotent dopaminerg behandling af neurologisk svækkelse, som er forbundet med hjerneskade
|
|
KR20050115913A
(ko)
|
2003-03-26 |
2005-12-08 |
사이토스 바이오테크놀로지 아게 |
Ｍｅｌａｎ―ａ 펩티드 유사체-바이러스-양-입자컨쥬게이트
|
|
US8906413B2
(en)
|
2003-05-12 |
2014-12-09 |
Supernus Pharmaceuticals, Inc. |
Drug formulations having reduced abuse potential
|
|
ATE545427T2
(de)
|
2003-05-29 |
2012-03-15 |
Shire Llc |
Gegen missbrauch geschützte amphetamin- verbindungen
|
|
EP1635815A4
(en)
|
2003-06-03 |
2009-03-25 |
Beth Israel Hospital |
METHOD AND COMPOUNDS FOR TREATING TISSUE TESTS
|
|
WO2004112723A2
(en)
|
2003-06-20 |
2004-12-29 |
Ronald Aung-Din |
Tropical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions
|
|
US7276608B2
(en)
|
2003-07-11 |
2007-10-02 |
Bristol-Myers Squibb Company |
Tetrahydroquinoline derivatives as cannabinoid receptor modulators
|
|
JP4174016B2
(ja)
|
2003-07-11 |
2008-10-29 |
株式会社ビーエル |
競合法によるサイロシン類のイムノクロマトグラフィー検出法及びテストキット
|
|
DE10334188B4
(de)
|
2003-07-26 |
2007-07-05 |
Schwarz Pharma Ag |
Verwendung von Rotigotin zur Behandlung von Depressionen
|
|
DE10338174A1
(de)
|
2003-08-20 |
2005-03-24 |
Lts Lohmann Therapie-Systeme Ag |
Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
|
|
US20050203011A1
(en)
|
2003-09-19 |
2005-09-15 |
The Regents Of The University Of California |
Mitigating symptoms and behaviors of substance abuse by modulating GDNF or BDNF pathway activity
|
|
US20050070501A1
(en)
|
2003-09-29 |
2005-03-31 |
New York Blood Center, Inc. |
Water dispersible film
|
|
JP4641942B2
(ja)
|
2003-10-03 |
2011-03-02 |
フェーイレン・ナムローゼ・フェンノートシャップ |
ヒトおよび動物におけるｉｇｆ−１血清レベルの低下と関連した種々の疾患状態の治療用の治療用組成物の製造のための血清中ｉｇｆ−１レベルを増加できる化合物の使用
|
|
US7517900B2
(en)
|
2003-10-10 |
2009-04-14 |
Bristol-Myers Squibb Company |
Pyrazole derivatives as cannabinoid receptor modulators
|
|
US20070053954A1
(en)
|
2003-10-24 |
2007-03-08 |
Rowe Stephen C |
Macromer-melt formulations
|
|
WO2005039502A2
(en)
|
2003-10-24 |
2005-05-06 |
Azopax Therapeutics Llc |
Macromer-melt formulations
|
|
JP2005132747A
(ja)
|
2003-10-29 |
2005-05-26 |
Ajinomoto Co Inc |
老齢伴侶動物の老化行動改善剤
|
|
WO2005058319A1
(en)
|
2003-12-16 |
2005-06-30 |
Cnsbio Pty Ltd |
Methods and compositions
|
|
US20050260258A1
(en)
|
2003-12-18 |
2005-11-24 |
The Texas A&M University System |
Use of vitelline protein B as a microencapsulating additive
|
|
WO2005063248A1
(en)
|
2003-12-22 |
2005-07-14 |
Sepracor Inc. |
Modafinil combination therapy for improving sleep quality
|
|
JP2007516275A
(ja)
|
2003-12-23 |
2007-06-21 |
ファイザー・プロダクツ・インク |
認知増強および精神病性障害のための治療的組合せ
|
|
GB0400802D0
(en)
|
2004-01-14 |
2004-02-18 |
Daniolabs Ltd |
Compounds for the treatment of disease
|
|
EP1715843A1
(en)
|
2004-01-29 |
2006-11-02 |
Neuromolecular Inc. |
Combination of a nmda receptor antagonist and a mao-inhibitor or a gadph-inhibitor for the treatment of central nervous system-related conditions
|
|
EP1727538A2
(en)
|
2004-02-13 |
2006-12-06 |
Neuromolecular Inc. |
Combination of an nmda receptor antagonist and an anti-epileptic drug for the treatment of epilepsy and other cns disorders
|
|
AU2005215775B2
(en)
|
2004-02-13 |
2011-02-03 |
Neuromolecular, Inc. |
Combination of a NMDA receptor antagonist and an anti-depressive drug MAO-inhibitor or a GADPH-inhibitor for the treatment of psychiatric conditions
|
|
WO2005082277A1
(en)
|
2004-02-18 |
2005-09-09 |
Stanford University |
Drug delivery systems using mesoporous oxide films
|
|
US20050222270A1
(en)
|
2004-02-26 |
2005-10-06 |
Olney John W |
Prolonged administration of NMDA antagonist drug and safener drug to create improved stable neural homeostasis
|
|
FR2867075B1
(fr)
|
2004-03-03 |
2006-07-14 |
Ethypharm Sa |
Procede de preparation de microspheres biodegradables calibrees
|
|
CA2559207A1
(en)
|
2004-03-12 |
2005-09-29 |
The Mclean Hospital Corporation |
Salvinorin derivatives and uses thereof
|
|
US20060270592A1
(en)
|
2004-03-19 |
2006-11-30 |
Ophthalmic Research Associates, Inc. |
Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
|
|
CA2567249A1
(en)
|
2004-04-19 |
2006-10-05 |
Jds Pharmaceuticals, Llc |
Lithium combinations, and uses related thereto
|
|
WO2005102390A2
(en)
|
2004-04-22 |
2005-11-03 |
Pfizer Japan, Inc. |
Combinations comprising alpha-2-delta ligands and nmda receptor antagonists
|
|
RU2253461C1
(ru)
|
2004-04-30 |
2005-06-10 |
Общество с ограниченной ответственностью "Паркинфарм" |
Фармацевтическая комбинация, оказывающая влияние на функционирование цнс, способ коррекции состояний, связанных с нарушениями функционирования цнс; фармацевтический набор; средство, способствующее проникновению через гематоэнцефалический барьер лекарственных субстанций и метаболитов; фармацевтическое средство для эндоназального применения
|
|
US20050255091A1
(en)
|
2004-05-14 |
2005-11-17 |
Loomis Gary L |
Hydrogels for biomedical applications
|
|
US20050261278A1
(en)
|
2004-05-21 |
2005-11-24 |
Weiner David M |
Selective serotonin receptor inverse agonists as therapeutics for disease
|
|
US20050265955A1
(en)
|
2004-05-28 |
2005-12-01 |
Mallinckrodt Inc. |
Sustained release preparations
|
|
NL1026634C2
(nl)
|
2004-07-12 |
2006-01-16 |
Willem Jacob Van Der Burg |
Psychofarmaceutisch preparaat en werkzame stof daarin.
|
|
US7799802B2
(en)
|
2004-08-03 |
2010-09-21 |
Institstute of Oriental Medical Science Inc. |
Method and health food for preventing and/or alleviating psychiatric disorder, and/or for effectuating sedation
|
|
US20060030625A1
(en)
|
2004-08-06 |
2006-02-09 |
Cheryle Ram Hart |
Dietary neurotransmitter precursors for balanced synthesis of neurotransmitters
|
|
US20060045865A1
(en)
|
2004-08-27 |
2006-03-02 |
Spherics, Inc. |
Controlled regional oral delivery
|
|
DK1804836T3
(da)
|
2004-09-24 |
2011-01-24 |
Beth Israel Hospital |
Fremgangsmåder til diagnosticering og behandling af graviditetskomplikationer
|
|
AU2005300045A1
(en)
|
2004-09-27 |
2006-05-04 |
Organix, Inc. |
Indole compounds useful as serotonin selective agents
|
|
WO2006042249A2
(en)
|
2004-10-08 |
2006-04-20 |
Neuromolecular Pharmaceuticals, Inc. |
Methods and compositions for treating migraine pain
|
|
EP1814591A4
(en)
|
2004-11-22 |
2009-04-22 |
Anadis Ltd |
BIOACTIVE PREPARATIONS
|
|
FR2878161B1
(fr)
|
2004-11-23 |
2008-10-31 |
Flamel Technologies Sa |
Forme medicamenteuse orale, solide et concue pour eviter le mesusage
|
|
FR2878158B1
(fr)
|
2004-11-24 |
2009-01-16 |
Flamel Technologies Sa |
Forme pharmaceutique orale, microparticulaire solide concue pour eviter le mesusage
|
|
US20060110327A1
(en)
|
2004-11-24 |
2006-05-25 |
Acura Pharmaceuticals, Inc. |
Methods and compositions for deterring abuse of orally administered pharmaceutical products
|
|
US7294649B2
(en)
|
2004-12-17 |
2007-11-13 |
Roche Diagnostics Operatins, Inc. |
Methamphetamine derivatives and conjugates for immunoassay
|
|
US8512751B2
(en)
|
2004-12-20 |
2013-08-20 |
Collegium Pharmaceutical, Inc. |
Pharmaceutical compositions for sleep disorders
|
|
PL1844189T3
(pl)
|
2005-01-10 |
2021-10-25 |
Smiths Detection Inc. |
Sposób przygotowania wymazówki
|
|
DE102005004343A1
(de)
|
2005-01-25 |
2006-08-10 |
Eberhard-Karls-Universität Tübingen Universitätsklinikum |
Behandlung von Phantomphänomenen
|
|
FR2881652B1
(fr)
|
2005-02-08 |
2007-05-25 |
Flamel Technologies Sa |
Forme pharmaceutique orale microparticulaire anti-mesuage
|
|
US8318210B2
(en)
|
2005-02-28 |
2012-11-27 |
Neos Therapeutics, Lp |
Compositions and methods of making sustained release liquid formulations
|
|
MX2007011250A
(es)
|
2005-03-21 |
2007-11-14 |
Ivax Pharmaceuticals Sro |
Inhibidor de la cristalizacion y su uso en capsulas de gelatina.
|
|
WO2006103407A2
(en)
|
2005-03-28 |
2006-10-05 |
Orexo Ab |
New pharmaceutical compositions useful in the treatment of migraine
|
|
US20060229293A1
(en)
|
2005-04-06 |
2006-10-12 |
Addiction Research Institute, Inc. |
Compositions for the treatment of hepatitis C and methods for using compositions for the treatment of hepatitis C
|
|
WO2007004067A2
(en)
|
2005-04-15 |
2007-01-11 |
Interface Biologics Inc. |
Methods and compositions for the delivery of biologically active agents
|
|
JP2008537961A
(ja)
|
2005-04-15 |
2008-10-02 |
ボード、オブ、トラスティーズ、オブ、ミシガン、ステイト、ユニバーシティ |
Ｇｐｃｒモジュレーター
|
|
BRPI0610046A2
(pt)
|
2005-04-22 |
2010-05-25 |
Wyeth Corp |
derivados de benzodioxano e benzodioxolano e usos destes
|
|
US7439496B2
(en)
|
2005-05-06 |
2008-10-21 |
Smiths Detection Inc. |
Chemical identification of peroxide-based explosives
|
|
US8859585B2
(en)
|
2005-05-25 |
2014-10-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Scopolamine for the treatment of depression and anxiety
|
|
GB0511060D0
(en)
|
2005-05-31 |
2005-07-06 |
Novartis Ag |
Organic compounds
|
|
CA2610838A1
(en)
|
2005-06-07 |
2006-12-14 |
Ramot At Tel Aviv University Ltd. |
Novel salts of conjugated psychotropic drugs and processes of preparing same
|
|
CA2612309C
(en)
|
2005-06-16 |
2014-12-16 |
Mohammed Saeed |
Composition and method for inhibiting, preventing, or ameliorating complications associated with ingestion of a medicinal, chemical, or biological substance or agent
|
|
US7645802B2
(en)
|
2005-06-27 |
2010-01-12 |
Biovail Laboratories International Srl. |
Bupropion hydrobromide and therapeutic applications
|
|
EP1906937B1
(en)
|
2005-07-22 |
2016-10-19 |
Rubicon Research Pvt Ltd. |
Novel dispersible tablet composition
|
|
US8852638B2
(en)
|
2005-09-30 |
2014-10-07 |
Durect Corporation |
Sustained release small molecule drug formulation
|
|
US20070092586A1
(en)
|
2005-10-26 |
2007-04-26 |
Alamo Pharmaceuticals |
Compositions and methods for the administration psychotropic drugs which modulate body weight
|
|
DE102005055866A1
(de)
|
2005-11-23 |
2007-05-24 |
Hte Ag The High Throughput Experimentation Company |
Verfahren zur Herstellung von Aryl-Aryl gekoppelter Verbindungen
|
|
EP1991207A2
(en)
|
2006-01-21 |
2008-11-19 |
Abbott GmbH & Co. KG |
Dosage form and method for the delivery of drugs of abuse
|
|
JP2009525124A
(ja)
|
2006-02-02 |
2009-07-09 |
メドロジックス・ディバイス・コーポレーション |
ゾル−ゲル組成物を含む生物活性材料送達系
|
|
US20070203216A1
(en)
|
2006-02-14 |
2007-08-30 |
Bjarke Ebert |
Method of treating inflammatory diseases
|
|
US20070190130A1
(en)
|
2006-02-16 |
2007-08-16 |
Mark William A |
Protein hydrolysate excipients
|
|
GB2449819A
(en)
|
2006-02-28 |
2008-12-03 |
Univ California |
Genes differentially expressed in bipolar disorder and/or schizophrenia
|
|
CN101460060A
(zh)
|
2006-03-01 |
2009-06-17 |
特莱斯特拉塔公司 |
局部治疗焦油响应性皮肤病用的组合物和方法
|
|
FR2898271B1
(fr)
|
2006-03-09 |
2009-01-16 |
Pierre Fabre Medicament Sa |
Nouvelle utilisation d'agents antihistaminiques pour le traitement preventif ou procede de syndromes inflammatoires, en particulier ceux declenches par les toga virus.
|
|
US8785500B2
(en)
|
2006-03-22 |
2014-07-22 |
Icahn School Of Medicine At Mount Sinai |
Intranasal administration of ketamine to treat depression
|
|
WO2006079999A2
(en)
|
2006-04-09 |
2006-08-03 |
Barth Frederik H |
Induction of a novel state of mind with a 5-ht2a agonist and a nmda antagonist
|
|
AU2007262448A1
(en)
|
2006-04-14 |
2007-12-27 |
Interface Biologics Incorporated |
Grafted polymers and uses thereof
|
|
GB0608647D0
(en)
|
2006-05-02 |
2006-06-14 |
Haritou Susan J A |
Methods of diagnosis and treatment
|
|
EP2023900B1
(en)
|
2006-05-12 |
2014-12-24 |
Shire LLC |
Controlled dose drug delivery system
|
|
US8846100B2
(en)
|
2006-05-12 |
2014-09-30 |
Shire Llc |
Controlled dose drug delivery system
|
|
ES2383768T3
(es)
|
2006-06-28 |
2012-06-26 |
Chelsea Therapeutics Inc. |
Composiciones farmacéuticas que comprenden droxidopa
|
|
EP2040758A4
(en)
|
2006-06-30 |
2014-09-17 |
Interface Biologics Inc |
BIORESPONSIVE POLYMERS
|
|
AU2007274583B2
(en)
|
2006-07-17 |
2012-11-01 |
Bar-Ilan University |
Conjugates comprising a psychotropic drug or a GABA agonist and an organic acid and their use in treating pain and other CNS disorders
|
|
JP2009543812A
(ja)
|
2006-07-20 |
2009-12-10 |
キャスケイド・セラピューティクス・インコーポレイテッド |
５−ＨＴ２Ｃリガンドとしてのテトラヒドロ−５Ｈ−ピリド［２，３−ｄ］アゼピン
|
|
US20080026189A1
(en)
|
2006-07-27 |
2008-01-31 |
Chun-Wei Lin |
Thin key structure for generating dazzling light
|
|
CA2661495C
(en)
|
2006-08-23 |
2017-05-02 |
The University Of Montana |
Method of reducing neuronal cell damage
|
|
SA07280459B1
(ar)
|
2006-08-25 |
2011-07-20 |
بيورديو فارما إل. بي. |
أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
|
|
WO2008026046A1
(en)
|
2006-08-30 |
2008-03-06 |
Pfizer Products Inc. |
Morpholine d3 dopamine antagonists
|
|
WO2008027526A1
(en)
|
2006-08-31 |
2008-03-06 |
Biogen Idec Ma Inc. |
Methods relating to peripheral administration of nogo receptor polypeptides
|
|
WO2008036678A2
(en)
|
2006-09-19 |
2008-03-27 |
Braincells, Inc. |
Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis
|
|
US20080066739A1
(en)
|
2006-09-20 |
2008-03-20 |
Lemahieu Edward |
Methods and systems of delivering medication via inhalation
|
|
CA2664935A1
(en)
|
2006-09-26 |
2008-04-03 |
Addiction Research Institute, Inc. |
Compositions for the treatment of hepatitis c and methods for using compositions for the treatment of hepatitis c
|
|
WO2008038291A1
(en)
|
2006-09-27 |
2008-04-03 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Combination of liposomal anti-cancer drugs and lysosome/endosome ph increasing agents for therapy
|
|
AU2007309390A1
(en)
|
2006-10-27 |
2008-05-02 |
Medivation Neurology, Inc. |
Methods and combination therapies for treating Alzheimer's disease
|
|
BRPI0718318A2
(pt)
|
2006-10-27 |
2013-11-26 |
Janssen Pharmaceutica Nv |
Processos para tratamento de distúrbios de perturbação de comportamento.
|
|
US20080103199A1
(en)
|
2006-10-31 |
2008-05-01 |
Haas Magali |
Treatment of pervasive developmental disorders
|
|
US20080293695A1
(en)
|
2007-05-22 |
2008-11-27 |
David William Bristol |
Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance
|
|
US8653106B2
(en)
|
2010-07-30 |
2014-02-18 |
Pisgah Laboratories, Inc. |
Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder
|
|
US7718649B1
(en)
|
2006-11-10 |
2010-05-18 |
Pisgah Labs, Inc. |
Physical states of a pharmaceutical drug substance
|
|
US7772222B2
(en)
|
2007-02-08 |
2010-08-10 |
Mickle Travis C |
Polar hydrophilic prodrugs of amphetamine and other stimulants and processes for making and using the same
|
|
ATE509622T1
(de)
|
2006-12-11 |
2011-06-15 |
Kempharm Inc |
Amphetamin-ornithine konjugate sowie herstellungs-und verwendungsverfahren
|
|
ES2302650B1
(es)
|
2007-01-11 |
2009-02-16 |
Tedec-Meiji Farma, S.A. |
Composicion de rapida desintegracion en la cavidad bucal.
|
|
CA2677205A1
(en)
|
2007-01-31 |
2008-08-07 |
University Of Virginia Patent Foundation |
Topiramate plus naltrexone for the treatment of addictive disorders
|
|
US8008285B2
(en)
|
2007-03-09 |
2011-08-30 |
Chelsea Therapeutics, Inc. |
Droxidopa and pharmaceutical composition thereof for the treatment of fibromyalgia
|
|
WO2008112773A2
(en)
|
2007-03-12 |
2008-09-18 |
Chelsea Therapeutics, Inc. |
Droxidopa and pharmaceutical composition thereof for the treatment of neurally mediated hypotension
|
|
WO2008115797A1
(en)
|
2007-03-16 |
2008-09-25 |
Pavo, Inc. |
Therapeutic compositions and methods
|
|
DE102007014286A1
(de)
|
2007-03-19 |
2008-09-25 |
Universität Tübingen |
Fluorsubstituierte Amphetamine und Amphetaminderivate und deren Verwendung
|
|
US10668058B2
(en)
|
2007-03-30 |
2020-06-02 |
Philip Morris Products S.A. |
Device and method for delivery of a medicament
|
|
AT505086B1
(de)
|
2007-04-02 |
2009-06-15 |
Planta Naturstoffe Vertriebsge |
Pharmazeutisches mittel gegen juckreiz und juckreizbedingten schmerz
|
|
WO2008122990A1
(en)
|
2007-04-04 |
2008-10-16 |
Almet Corporation Limited |
Compacting upflow extractor and method of using it
|
|
US8747832B2
(en)
|
2007-04-12 |
2014-06-10 |
Rutgers, The State University Of New Jersey |
Biodegradable polyanhydrides with natural bioactive molecules
|
|
PL2172471T3
(pl)
|
2007-04-18 |
2013-08-30 |
Teva Pharma |
Sposób otrzymywania produktów pośrednich inhibitorów reduktazy HMG-CoA
|
|
US7638651B2
(en)
|
2007-04-26 |
2009-12-29 |
Auspex Pharmaceuticals |
Substituted cyclohexanones
|
|
US10183001B1
(en)
|
2007-05-22 |
2019-01-22 |
Pisgah Laboratories, Inc. |
Opioid and attention deficit hyperactivity disorder medications possessing abuse deterrent and anti-dose dumping safety features
|
|
US9421266B2
(en)
|
2007-05-22 |
2016-08-23 |
Pisgah Laboratories, Inc. |
Safety of pseudoephedrine drug products
|
|
TW200924785A
(en)
|
2007-07-31 |
2009-06-16 |
Limerick Biopharma Inc |
Phosphorylated pyrone analogs and methods
|
|
WO2009020897A1
(en)
|
2007-08-03 |
2009-02-12 |
Forest Laboratories Holdings Limited |
Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine recptor ligands
|
|
FR2919861A1
(fr)
|
2007-08-06 |
2009-02-13 |
Sanofi Aventis Sa |
Le solvate d'isopranol de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
|
|
AU2016208412A1
(en)
|
2007-08-06 |
2016-08-18 |
Biotie Therapies, Inc. |
Methods for treating dependence
|
|
MX357542B
(es)
|
2007-08-06 |
2018-07-13 |
Biotie Therapies Inc |
Nepicastat para usarse en el tratamiento de dependencia.
|
|
WO2009019472A1
(en)
|
2007-08-07 |
2009-02-12 |
Prosarix Limited |
1, 2, 4 -triazole derivatives as serotonergic modulators
|
|
US8067028B2
(en)
|
2007-08-13 |
2011-11-29 |
Confluent Surgical Inc. |
Drug delivery device
|
|
WO2009035473A2
(en)
|
2007-09-13 |
2009-03-19 |
Sanfilippo Louis C |
Method of treating binge eating disorder, obesity resulting from binge eating behavior and depressive disorders
|
|
EP2203498B1
(en)
|
2007-10-05 |
2017-12-06 |
Interface Biologics Inc. |
Oligofluorinated cross-linked polymers and uses thereof
|
|
WO2009049215A1
(en)
|
2007-10-10 |
2009-04-16 |
Wake Forest University Health Sciences |
Methods to reduce the effects of sleep deprivation
|
|
WO2009055001A2
(en)
|
2007-10-23 |
2009-04-30 |
Fred Hutchinson Cancer Research Center |
Methods of treating aging and methods of screening candidate agents therefor
|
|
WO2009061436A1
(en)
|
2007-11-06 |
2009-05-14 |
University Of Florida Research Foundation |
Compound for activating 5-ht2c receptors in combination with an amphetamine compound
|
|
DE102007063210A1
(de)
|
2007-12-20 |
2009-06-25 |
Eberhard-Karls-Universität Tübingen Universitätsklinikum |
Arzneimittel zur Behandlung von Phantomphänomenen
|
|
WO2009079765A1
(en)
|
2007-12-21 |
2009-07-02 |
Cascade Therapeutics Inc. |
Compounds with activity at the 5-ht2c receptor
|
|
US20090176792A1
(en)
|
2008-01-07 |
2009-07-09 |
Auspex Pharmaceuticals, Inc. |
Substituted dibenzhydrylpiperazines
|
|
EP3090743A1
(en)
|
2008-01-09 |
2016-11-09 |
Charleston Laboratories, Inc. |
Pharmaceutical compositions for treating headache and eliminating nausea
|
|
WO2009091605A2
(en)
|
2008-01-17 |
2009-07-23 |
Health Innovations, Llc |
Taste titration therapies
|
|
WO2009097596A1
(en)
|
2008-01-31 |
2009-08-06 |
Paul Griffin |
Compositions and methods for the treatment of chronic infections
|
|
US8329663B2
(en)
|
2008-01-31 |
2012-12-11 |
Paul Griffin |
Compositions and methods for the treatment of chronic infections
|
|
JP6088123B2
(ja)
|
2008-02-01 |
2017-03-01 |
アルファ−オー・ペプチドズ・アーゲーＡｌｐｈａ−Ｏ Ｐｅｐｔｉｄｅｓ Ａｇ |
ワクチンとして有用な自己会合ペプチドナノ粒子
|
|
WO2009095479A2
(en)
|
2008-02-01 |
2009-08-06 |
Ascendis Pharma As |
Prodrug comprising a self-cleavable linker
|
|
US20090198145A1
(en)
|
2008-02-06 |
2009-08-06 |
Chow Harrison |
Compositions, methods, and systems for rapid induction and maintenance of continuous rem sleep
|
|
JP2011511810A
(ja)
|
2008-02-11 |
2011-04-14 |
オーガニクス インコーポレイテッド |
インドール化合物およびその使用方法
|
|
US8859579B2
(en)
|
2008-03-21 |
2014-10-14 |
Richard Andrew Sewell |
Compostions and methods for preventing and/or treating disorders associated with cephalic pain
|
|
CA2718534A1
(en)
|
2008-03-26 |
2009-10-01 |
Lonza Ltd |
Process for the synthesis of ethynylcyclopropane
|
|
US20170276676A1
(en)
|
2008-03-27 |
2017-09-28 |
Gus J. Slotman |
System for assessing drug efficacy and response of a patient to therapy
|
|
WO2009118763A1
(en)
|
2008-03-28 |
2009-10-01 |
Panacea Biotec Limited |
Multilayered pharmaceutical compositions and processes thereof
|
|
US20090252786A1
(en)
|
2008-03-31 |
2009-10-08 |
Christoph Hanz |
Use of a Biologically Active Blood Serum for the Treatment of a Disorder Characterized in a Reduced Function of a GABA Receptor
|
|
EP2106799A1
(en)
|
2008-03-31 |
2009-10-07 |
OWEN Holding LTD |
Use of a biologically active blood serum for the treatment of a disorder characterized in a reduced function of a GABA receptor
|
|
FR2930147B1
(fr)
|
2008-04-18 |
2013-02-08 |
Flamel Tech Sa |
Forme orale solide dotee d'un double profil de liberation
|
|
ES2527448T3
(es)
|
2008-04-28 |
2015-01-23 |
Zogenix, Inc. |
Nuevas formulaciones para el tratamiento de la migraña
|
|
US20110086063A1
(en)
|
2008-06-04 |
2011-04-14 |
Cornell University |
Vaccines for prevention and treatment of addiction
|
|
US10388179B2
(en)
|
2008-06-18 |
2019-08-20 |
Accenture Global Solutions Limited |
Analytics platform
|
|
JP5620907B2
(ja)
|
2008-06-19 |
2014-11-05 |
エルテーエスローマン テラピー−ジステーメ アーゲー |
カチオン性活性剤の経皮送達のための組成物
|
|
EP2313037A1
(en)
|
2008-06-30 |
2011-04-27 |
Oron Zachar |
Dermal application of vasoconstrictors
|
|
US9642819B2
(en)
|
2008-07-10 |
2017-05-09 |
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical |
Low dosage serotonin 5-HT2A receptor agonist to suppress inflammation
|
|
US8617607B2
(en)
|
2008-07-10 |
2013-12-31 |
Tyrx, Inc. |
Sustained release formulations of psychoactive drugs
|
|
JP2011529923A
(ja)
|
2008-08-06 |
2011-12-15 |
ゴスフォース センター（ホールディングス）プロプライエタリー リミテッド |
精神障害（ｐｓｙｃｈｉａｔｒｉｃｄｉｓｏｒｄｅｒ）を治療するための組成物および方法
|
|
FR2935611B1
(fr)
|
2008-09-10 |
2010-10-15 |
Commissariat Energie Atomique |
Utilisation d'agents anti-connexines pour moduler l'effet therapeutique de molecules psychotropes
|
|
FR2936710B1
(fr)
|
2008-10-07 |
2011-01-07 |
Ceva Sante Animale |
Composition veterinaire antiprolactinique destinee aux ruminants
|
|
EP3006024B1
(en)
|
2009-01-20 |
2019-03-20 |
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center |
Benzoic acid or salts thereof to enhance the activity of a neuropharmaceutical
|
|
UA105657C2
(uk)
|
2009-02-27 |
2014-06-10 |
Хелсінн Терапьютікс (Ю.Ес.), Інк. |
Поліпшені способи лікування мігрені на основі анамореліну
|
|
WO2010124089A2
(en)
|
2009-04-22 |
2010-10-28 |
Synosia Therapeutics, Inc. |
Methods for treating dependence
|
|
US20120159656A1
(en)
|
2009-04-24 |
2012-06-21 |
Galenea Corp. |
Compositions and methods for evaluating cognitive defects
|
|
MX2011012596A
(es)
|
2009-05-26 |
2012-04-02 |
Shire Llc |
Metodos para incrementar os efectos de un inhibidor selectivo de la recaptacion de serotonina en los mamiferos.
|
|
GB201111485D0
(en)
|
2011-07-05 |
2011-08-17 |
Biocopea Ltd |
Drug composition and its use in therapy
|
|
US20110306596A1
(en)
|
2009-07-27 |
2011-12-15 |
Auspex Pharmaceuticals, Inc. |
Benzazepine inhibitors of gamma-secretase
|
|
WO2011020030A2
(en)
|
2009-08-13 |
2011-02-17 |
The General Hospital Corporation |
Methods and compositions to prevent addiction
|
|
US20110038915A1
(en)
|
2009-08-14 |
2011-02-17 |
Eduardo Jose Gonzalez |
Chewing Gum Formula for Enhancing Psycho-Spirituality
|
|
WO2011028875A1
(en)
|
2009-09-03 |
2011-03-10 |
Wake Forest University Health Sciences |
Immunogenic conjugates for producing immune responses to drugs of abuse and methods of use
|
|
FR2954167A1
(fr)
|
2009-09-04 |
2011-06-24 |
Centre Nat Rech Scient |
Traitement par l'ocytocine de caracteristiques comportementales associees a l'autisme et a la timidite pathologique
|
|
FR2951378B1
(fr)
|
2009-10-16 |
2012-06-01 |
Flamel Tech Sa |
Forme pharmaceutique orale solide anti-mesusage et dotee d'un profil specifique de liberation modifiee
|
|
CN102596278B
(zh)
|
2009-10-16 |
2016-06-29 |
帝斯曼知识产权资产管理有限公司 |
包含含有双-(α-氨基-二醇-二酯)的聚酯酰胺的涂层
|
|
US20120321706A1
(en)
|
2009-10-19 |
2012-12-20 |
Intec Pharma Ltd. |
Novel gastroretentive dosage forms of poorly soluble drugs
|
|
WO2011072398A1
(en)
|
2009-12-18 |
2011-06-23 |
Interface Biologics, Inc. |
Local delivery of drugs from self assembled coatings
|
|
JP5792748B2
(ja)
|
2010-02-06 |
2015-10-14 |
タール ファーマシューティカルズ，インコーポレイテッド |
結晶化法及びバイオアベイラビリティ
|
|
CA2829180C
(en)
|
2010-03-05 |
2019-01-15 |
Newagriculture, Inc. |
Leaf protein-lipid-soluble material complexes
|
|
US20110217289A1
(en)
|
2010-03-05 |
2011-09-08 |
Basf Se |
Melt-Coated Dosage Forms
|
|
CN102892429B
(zh)
|
2010-03-17 |
2016-08-31 |
康奈尔大学 |
基于被破坏的腺病毒的抗滥用药物疫苗
|
|
WO2011138142A1
(en)
|
2010-05-07 |
2011-11-10 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Compositions and use of sulfasalazine
|
|
BR112012028717A2
(pt)
|
2010-05-10 |
2016-07-19 |
Segetis Inc |
formulações de cuidados pessoais contendo ésteres de cetal alquílicos e métodos de fabricação
|
|
US8362007B1
(en)
|
2010-05-11 |
2013-01-29 |
Demerx, Inc. |
Substituted noribogaine
|
|
US8765737B1
(en)
|
2010-05-11 |
2014-07-01 |
Demerx, Inc. |
Methods and compositions for preparing and purifying noribogaine
|
|
US20120108510A1
(en)
|
2010-05-20 |
2012-05-03 |
Emory University |
Methods of improving behavioral therapies
|
|
JP2012020991A
(ja)
|
2010-06-16 |
2012-02-02 |
Takasago Internatl Corp |
経皮吸収促進剤、及びこれを含有する皮膚外用製剤
|
|
US8802832B2
(en)
|
2010-06-22 |
2014-08-12 |
Demerx, Inc. |
Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
|
|
UA111065C2
(uk)
|
2010-07-23 |
2016-03-25 |
Демеркс, Інк. |
Композиції норибогаїну
|
|
WO2012022928A2
(en)
|
2010-08-20 |
2012-02-23 |
Heptares Therapeutic Ltd |
Biological materials and uses thereof
|
|
US20130295012A1
(en)
|
2010-08-30 |
2013-11-07 |
President And Fellows Of Harvard College |
Shear controlled release for stenotic lesions and thrombolytic therapies
|
|
WO2012031125A2
(en)
|
2010-09-01 |
2012-03-08 |
The General Hospital Corporation |
Reversal of general anesthesia by administration of methylphenidate, amphetamine, modafinil, amantadine, and/or caffeine
|
|
US20120129834A1
(en)
|
2010-09-17 |
2012-05-24 |
Buck Institute For Research On Aging |
Serotonin receptor antagonists for use in the treatment of huntington's disease
|
|
DK2618826T3
(en)
|
2010-09-20 |
2016-08-01 |
A Carlsson Res Ab |
Phenylpiperdine FOR TREATMENT OF DEMENTIA
|
|
AU2011313814B2
(en)
|
2010-10-07 |
2015-12-24 |
Eaglepharma Pty Ltd |
Combination therapy for the treatment of depression and other non-infectious diseases
|
|
WO2012054815A1
(en)
|
2010-10-22 |
2012-04-26 |
Duke University |
Slow-release formulations of 5-hydroxytryptophan as an adjunct to pro-serotonergic therapies
|
|
US20130230587A1
(en)
|
2010-11-10 |
2013-09-05 |
Rubicon Research Private Limited |
Sustained release compositions
|
|
ES2673219T3
(es)
|
2010-11-15 |
2018-06-20 |
Neuroderm Ltd |
Composición para la entrega transdérmica de agentes activos
|
|
EP2649443A2
(en)
|
2010-12-06 |
2013-10-16 |
Ramot at Tel-Aviv University Ltd |
Methods and kits for detection of drugs
|
|
EP3834869A1
(en)
|
2010-12-22 |
2021-06-16 |
Syqe Medical Ltd. |
System for drug delivery
|
|
EP2481740B1
(en)
|
2011-01-26 |
2015-11-04 |
DemeRx, Inc. |
Methods and compositions for preparing noribogaine from voacangine
|
|
FR2971423B1
(fr)
|
2011-02-15 |
2014-01-10 |
Ceva Sante Animale |
Composition veterinaire antiprolactinique destinee aux ruminants
|
|
EP2691777A1
(en)
|
2011-03-28 |
2014-02-05 |
Flir Systems, Inc. |
Detection of analytes including drugs
|
|
US8742096B2
(en)
|
2011-03-28 |
2014-06-03 |
Demerx, Inc. |
Methods and compositions for preparing noribogaine from voacangine
|
|
AR085840A1
(es)
|
2011-04-05 |
2013-10-30 |
Otsuka Pharma Co Ltd |
Medicamento que contiene un compuesto que es 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoxi]-1h-quinolin-2-ona
|
|
US20120282255A1
(en)
|
2011-04-07 |
2012-11-08 |
Greg Plucinski |
Methods and compositions for the treatment of alcoholism and alcohol dependence
|
|
KR20120128440A
(ko)
|
2011-05-17 |
2012-11-27 |
삼성전자주식회사 |
표적 물질 검출용 키트 및 이를 이용한 표적 물질 검출 방법
|
|
US20140163070A1
(en)
|
2012-05-17 |
2014-06-12 |
Bruce Roseman |
Treatment for cerebral palsy impaired speech in children
|
|
US9089563B2
(en)
|
2011-05-19 |
2015-07-28 |
Gilrose Pharmaceuticals, Llc |
Method of treating apraxia of speech in children
|
|
KR20140042868A
(ko)
|
2011-06-23 |
2014-04-07 |
맵 파마슈티컬스, 인코포레이티드 |
신규한 플루오로에르골린 유사체
|
|
BR112014005064A2
(pt)
|
2011-09-15 |
2017-04-04 |
Demerx Inc |
não solvatos de sal de norigobaína
|
|
WO2013061161A2
(en)
|
2011-10-28 |
2013-05-02 |
Green Bcn Consulting Services Sl |
New combination therapies for treating neurological disorders
|
|
US9493517B2
(en)
|
2011-11-07 |
2016-11-15 |
Glaxosmithkline Biologicals Sa |
Conjugates comprising an antigen and a carrier molecule
|
|
FR2983409B1
(fr)
|
2011-12-06 |
2013-12-27 |
Ethypharm Sa |
Comprime susceptible de lutter contre le detournement par voie injectable
|
|
IN2014CN04160A
(ko)
|
2011-12-08 |
2015-07-17 |
Demerx Inc |
|
|
CA2855990A1
(en)
|
2011-12-09 |
2013-06-13 |
Demerx, Inc. |
Sulfate esters of noribogaine
|
|
EP2788003A4
(en)
|
2011-12-09 |
2015-05-27 |
Demerx Inc |
PHOSPHATESTER OF NORIBOGAIN
|
|
EP2607352A1
(en)
|
2011-12-22 |
2013-06-26 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Pipecolate-diketoamides for treatment of psychiatric disorders
|
|
EP2610245A1
(en)
|
2011-12-28 |
2013-07-03 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Pipecolate-sulfonamides for treatment of psychiatric disorders
|
|
CA2858105A1
(en)
|
2012-01-25 |
2013-08-01 |
Demerx, Inc. |
Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them
|
|
EP2807168A4
(en)
|
2012-01-25 |
2015-10-14 |
Demerx Inc |
SYNTHETIC VOACANGINE
|
|
WO2013112163A1
(en)
|
2012-01-25 |
2013-08-01 |
Demerx, Inc. |
Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them
|
|
EP2649989B1
(en)
|
2012-04-13 |
2017-10-18 |
King Saud University |
Method for preparing a solid dispersion, solid dispersion obtained thereby and use thereof
|
|
US20130295170A1
(en)
|
2012-05-03 |
2013-11-07 |
Kydes Pharmaceuticals Llc |
Compositions for control of drug abuse
|
|
US20130295016A1
(en)
|
2012-05-07 |
2013-11-07 |
David J. Gerber |
Signatures of electroencephalographic oscillations
|
|
JP6177885B2
(ja)
|
2012-05-09 |
2017-08-09 |
カンテックス ファーマシューティカルズ， インコーポレイテッド |
骨髄抑制の処置
|
|
US8784835B2
(en)
|
2012-07-02 |
2014-07-22 |
Trent Austin |
Method for producing muscimol and/or reducing ibotenic acid from amanita tissue
|
|
WO2014008118A2
(en)
|
2012-07-02 |
2014-01-09 |
The General Hospital Corporation |
Method for concurrent treatment of pain and depression
|
|
EP2690102A1
(en)
|
2012-07-24 |
2014-01-29 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Bicyclic aza-amides for treatment of psychiatric disorders
|
|
US9622971B2
(en)
|
2012-08-17 |
2017-04-18 |
Smartek International Llc |
Preparation of desiccated liposomes for use in compressible delivery systems
|
|
JP6434408B2
(ja)
|
2012-08-24 |
2018-12-05 |
インテグアールエックス セラピューティクス， エルエルシーＩｎｔｅｇｕｒｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｌｌｃ |
治療剤の経皮送達を増強するための化学組成物および方法
|
|
WO2014035473A1
(en)
|
2012-08-31 |
2014-03-06 |
Zoll Medical Corporation |
Cardiac resuscitation methods and kits
|
|
US20140100282A1
(en)
|
2012-10-10 |
2014-04-10 |
Patrick S L Wong |
Intranasal administration of pharmaceutical agents for treatment of neurological diseases
|
|
US20150231300A1
(en)
|
2012-10-28 |
2015-08-20 |
Peritech Pharma Ltd. |
Pharmaceutical liquid adhesive compositions for treatment of anorectal disorders
|
|
WO2014078857A1
(en)
|
2012-11-19 |
2014-05-22 |
Regents Of The University Of Minnesota |
Ergoline derivatives as dopamine receptor modulators
|
|
WO2014093277A1
(en)
|
2012-12-11 |
2014-06-19 |
The Mclean Hospital Corporation |
Xenon and/or argon treatment as an adjunct to psychotherapy for psychiatric disorders
|
|
US9783535B2
(en)
|
2012-12-20 |
2017-10-10 |
Demerx, Inc. |
Substituted noribogaine
|
|
WO2014117089A1
(en)
|
2013-01-25 |
2014-07-31 |
Case Western Reserve University |
Compositions and methods for the treatment of pervasive development disorders
|
|
US20140294923A1
(en)
|
2013-02-20 |
2014-10-02 |
Questcor Pharmaceuticals, Inc. |
Acth for treatment of migraine headache
|
|
US20140255522A1
(en)
|
2013-03-10 |
2014-09-11 |
Peritech Pharma Ltd. |
Topical compositions and methods of treatment of anorectal and genital disorders
|
|
WO2014153099A2
(en)
|
2013-03-14 |
2014-09-25 |
Pulmonary Analytics |
Method for using exhaled breath to determine the presence of drug
|
|
WO2014143201A1
(en)
|
2013-03-15 |
2014-09-18 |
Demerx, Inc. |
Method for noribogaine treatment of addiction in patients on methadone
|
|
EA032064B1
(ru)
|
2013-03-15 |
2019-04-30 |
Мелиор Фармасьютикалз Ii, Ллс |
Способ лечения леводопа-индуцированной дискинезии с применением сиднокарба
|
|
WO2014142938A1
(en)
|
2013-03-15 |
2014-09-18 |
Aihol Corporation |
Pharmaceutical formulation containing glycosaminoglycan
|
|
WO2014146082A1
(en)
|
2013-03-15 |
2014-09-18 |
Bhl Patent Holdings Llc |
Materials and methods for treating neuropathies and related disorders including those involving a keystone nerve
|
|
WO2014176556A1
(en)
|
2013-04-26 |
2014-10-30 |
Express Diagnostics International, Inc. |
Portable testing system for detecting selected drugs or compounds in non-controlled environments
|
|
WO2014186623A2
(en)
|
2013-05-17 |
2014-11-20 |
Biomed Valley Discoveries |
Methods and compositions for the treatment of a chagas disease
|
|
JP6466417B2
(ja)
|
2013-05-29 |
2019-02-06 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
二峰性放出プロファイルを有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
|
|
CA2817728A1
(en)
|
2013-05-31 |
2014-11-30 |
Pharmascience Inc. |
Abuse deterrent immediate release formulation
|
|
CA2914583C
(en)
|
2013-06-04 |
2019-06-18 |
Vyome Biosciences Pvt. Ltd. |
Coated particles and compositions comprising same
|
|
WO2014197753A1
(en)
|
2013-06-08 |
2014-12-11 |
Sedogen, Llc |
Method of treating prader willi syndrome and conditions associated with low basal metabolic rate or hyperphagia
|
|
EP2818177A1
(en)
|
2013-06-24 |
2014-12-31 |
Celica, D.O.O. |
Mechanism and drug targets for reducing cell edema (neuroprotection) and cytoplasmic excitability in astrocytes in normal and pathological states
|
|
CA2916973A1
(en)
|
2013-07-03 |
2015-01-08 |
Acura Pharmaceuticals, Inc. |
Methods and compositions for deterring abuse
|
|
PE20160556A1
(es)
|
2013-07-08 |
2016-06-11 |
Auspex Pharmaceuticals Inc |
Compuestos neurotransmisores de dihidroxifenilo, composiciones y metodos
|
|
EA032465B1
(ru)
|
2013-07-12 |
2019-05-31 |
Грюненталь Гмбх |
Защищенная от применения не по назначению пероральная фармацевтическая лекарственная форма, содержащая этиленвинилацетатный полимер, и способ ее изготовления
|
|
US9770514B2
(en)
|
2013-09-03 |
2017-09-26 |
ExxPharma Therapeutics LLC |
Tamper-resistant pharmaceutical dosage forms
|
|
US10098893B2
(en)
|
2013-10-03 |
2018-10-16 |
Northwestern University |
Methods of administering a trace amine-associated receptor 1 (TAAR1) agonist to patients having the minor allele of the single nucleotide polymorphism rs2237457
|
|
US9474481B2
(en)
|
2013-10-22 |
2016-10-25 |
Mindstrong, LLC |
Method and system for assessment of cognitive function based on electronic device usage
|
|
US9420970B2
(en)
|
2013-10-22 |
2016-08-23 |
Mindstrong, LLC |
Method and system for assessment of cognitive function based on mobile device usage
|
|
US20160256392A1
(en)
|
2013-10-31 |
2016-09-08 |
Cima Labs Inc. |
Abuse-deterrent dosage forms
|
|
WO2015065547A1
(en)
|
2013-10-31 |
2015-05-07 |
Cima Labs Inc. |
Immediate release abuse-deterrent granulated dosage forms
|
|
WO2015066344A1
(en)
|
2013-11-01 |
2015-05-07 |
Arena Pharmaceuticals, Inc. |
5-ht2c receptor agonists and compositions and methods of use
|
|
TW201605856A
(zh)
|
2013-11-01 |
2016-02-16 |
艾尼納製藥公司 |
５－ＨＴｃ受體促效劑
|
|
CN103549133A
(zh)
|
2013-11-05 |
2014-02-05 |
杨剑 |
有机猪牧草饲料
|
|
CN103535561A
(zh)
|
2013-11-05 |
2014-01-29 |
杨剑 |
饲养大猪用的牧草饲料
|
|
CN103751943B
(zh)
|
2014-01-13 |
2020-10-13 |
湖北及安盾消防科技有限公司 |
一种含有含氮类有机化合物的灭火组合物
|
|
WO2015112168A2
(en)
|
2014-01-24 |
2015-07-30 |
Demerx, Inc. |
Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
|
|
CN103773056B
(zh)
|
2014-01-24 |
2015-11-18 |
山东大学 |
高脆性透明类岩石材料试件制备方法
|
|
CA2978537C
(en)
|
2014-03-03 |
2023-10-24 |
Demerx, Inc. |
Therapeutic uses of ibogaine and related compounds
|
|
US20150258114A1
(en)
|
2014-03-13 |
2015-09-17 |
Demerx, Inc. |
Methods for acute and long-term treatment of substance abuse using ibogaine
|
|
US9662392B2
(en)
|
2014-06-03 |
2017-05-30 |
Pop Test Abuse Deterrent Technology Llc |
Drug device configured for wireless communication
|
|
CA2994218A1
(en)
|
2014-07-30 |
2016-02-04 |
Cleveland Biolabs, Inc. |
Flagellin compositons and uses
|
|
US10231651B2
(en)
|
2014-09-25 |
2019-03-19 |
Bae Systems Information And Electronic Systems Integration Inc. |
Gait authentication system and method thereof
|
|
US10058253B2
(en)
|
2014-11-11 |
2018-08-28 |
Zenmark, Llc |
System, method, and article for heart rate variability monitoring
|
|
WO2016145193A1
(en)
|
2015-03-10 |
2016-09-15 |
Eleusis Benefit Corporation, Pbc |
Lsd for the treatment of alzheimer's disease
|
|
US11298326B2
(en)
|
2015-03-24 |
2022-04-12 |
Kyowa Kirin Co., Ltd. |
Nucleic acid-containing lipid nanoparticles
|
|
US10254298B1
(en)
|
2015-03-25 |
2019-04-09 |
National Technology & Engineering Solutions Of Sandia, Llc |
Detection of metabolites for controlled substances
|
|
EP3277271B1
(en)
*
|
2015-03-31 |
2021-07-21 |
Turtle Bear Holdings, LLC |
Antiviral activity from medicinal mushrooms and their active constituents
|
|
CA3002544C
(en)
|
2015-04-27 |
2024-03-05 |
Arena Pharmaceuticals, Inc. |
5-ht2c receptor agonists and compositions and methods of use
|
|
CN107073293A
(zh)
|
2015-05-01 |
2017-08-18 |
托匹泰克以色列制药有限公司 |
用于治疗鼻出血的组合物
|
|
CA2968703A1
(en)
|
2015-05-19 |
2016-11-24 |
Joseph Robert Knight |
Method for isolation of alkaloids and amino acids, and compositions containing isolated alkaloids and amino acids
|
|
US20180147142A1
(en)
|
2015-05-19 |
2018-05-31 |
Joseph Robert Knight |
Method for isolation of alkaloids and amino acids, and compositions containing isolated alkaloids and amino acids
|
|
US9737759B2
(en)
|
2015-07-17 |
2017-08-22 |
Genesant Technologies, Inc. |
Automatic application-based exercise tracking system and method
|
|
JP6789578B2
(ja)
|
2015-07-31 |
2020-11-25 |
アリーナ ファーマシューティカルズ， インコーポレイテッド |
５−ｈｔ２ｃ受容体アゴニストおよび組成物、ならびに使用方法
|
|
US9614734B1
(en)
|
2015-09-10 |
2017-04-04 |
Pearson Education, Inc. |
Mobile device session analyzer
|
|
US20180021326A1
(en)
|
2016-07-23 |
2018-01-25 |
Paul Edward Stamets |
Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin
|
|
EA038219B1
(ru)
|
2016-08-19 |
2021-07-26 |
Арена Фармасьютикалз, Инк. |
Агонисты рецептора 5-ht2c и композиции, а также способ их применения
|
|
US10596378B2
(en)
|
2016-10-18 |
2020-03-24 |
Joseph Rustick |
Method for treatment of depression using synaptic pathway training
|
|
US20180195455A1
(en)
|
2017-01-12 |
2018-07-12 |
GM Global Technology Operations LLC |
Engine combustion phasing control during transient state
|
|
NL2018190B1
(en)
|
2017-01-18 |
2018-07-26 |
Procare Beheer B V |
Psilocybin or psilocin in combination with cannabinoid
|
|
CN110381960A
(zh)
|
2017-02-02 |
2019-10-25 |
麦克马斯特大学 |
作为抗微生物剂的增强剂的碳酸氢盐
|
|
CN110740728A
(zh)
*
|
2017-02-09 |
2020-01-31 |
卡马技术有限责任公司 |
包含裸头草碱衍生物的组合物和方法
|
|
WO2018145219A1
(es)
|
2017-02-09 |
2018-08-16 |
Serani Mostazal Jorge |
Composición farmaceutica para la prevención y tratamiento de las adicciones a traves de un contracondicionamiento aversivo
|
|
CN108619214A
(zh)
|
2017-03-15 |
2018-10-09 |
王慎君 |
一种治疗肿瘤的药物
|
|
MX2019011510A
(es)
|
2017-03-30 |
2020-01-09 |
Ojai Energetics Pbc |
Metodos y composiciones para mejorar la salud.
|
|
JP2020516682A
(ja)
|
2017-04-07 |
2020-06-11 |
エイシア セラピューティクス， インコーポレイテッド |
ピロロピリミジンキナーゼの薬学的な塩、物理的形態および組成物、ならびにその作製方法
|
|
WO2018195455A1
(en)
|
2017-04-20 |
2018-10-25 |
Eleusis Benefit Corporation, Pbc |
Assessing and treating psychedelic-responsive subjects
|
|
US20180343812A1
(en)
|
2017-05-31 |
2018-12-06 |
Insectergy, Llc |
Cannabis farming systems and methods
|
|
US20190246591A1
(en)
|
2017-05-31 |
2019-08-15 |
Insectergy, Llc |
Insect and cannabis production systems and methods
|
|
EP3629899A4
(en)
|
2017-06-02 |
2021-04-21 |
Northwestern University |
THIN, SOFT, SKIN-MOUNTED MICROFLUIDIC NETWORKS FOR DETECTION AND ANALYSIS OF TARGET SUBSTANCES IN SWEAT
|
|
CN107252080A
(zh)
|
2017-07-12 |
2017-10-17 |
沈建国 |
一种麻菇酱油的配方
|
|
GB2571696B
(en)
|
2017-10-09 |
2020-05-27 |
Compass Pathways Ltd |
Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
|
|
EP3698260A4
(en)
|
2017-10-19 |
2021-08-04 |
Eleusis Health Solutions US, Inc. |
METHODS AND SYSTEMS FOR INCREASING THE SAFETY OF AWARENESS-ENHANCING DRUG THERAPIES
|
|
WO2019081764A1
(en)
|
2017-10-26 |
2019-05-02 |
Consejo Superior De Investigaciones Científicas (Csic) |
ASSOCIATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND / OR PSYCHIATRIC DISORDERS
|
|
WO2019099745A1
(en)
|
2017-11-16 |
2019-05-23 |
CaaMTech, LLC |
Compositions comprising a psilocybin derivative and a cannabinoid
|
|
US10703325B2
(en)
|
2017-11-27 |
2020-07-07 |
Autoliv Asp, Inc. |
Multi-chambered side airbag assemblies
|
|
CN112292153A
(zh)
|
2017-12-04 |
2021-01-29 |
D·勒库特 |
调节肝内皮细胞开窗的组合物和方法
|
|
FI128750B
(en)
|
2017-12-21 |
2020-11-30 |
Helsingin Yliopisto |
Methods for determining the therapeutic effect of fast-acting antidepressants and related individual antidepressant therapy
|
|
WO2019144140A1
(en)
|
2018-01-22 |
2019-07-25 |
CyPhi LLC |
Bio-mimetic formulation
|
|
WO2019161050A1
(en)
|
2018-02-18 |
2019-08-22 |
Akili Interactive Labs, Inc. |
Cognitive platform including computerized elements coupled with a therapy for mood disorder
|
|
AU2019232011A1
(en)
|
2018-03-08 |
2020-10-01 |
Compass Pathfinder Limited |
Processes for the production of tryptamines
|
|
FI129102B
(en)
|
2018-03-19 |
2021-07-15 |
Teknologian Tutkimuskeskus Vtt Oy |
Heterological production of psilosybin
|
|
US11426367B2
(en)
|
2018-05-04 |
2022-08-30 |
Perception Neuroscience, Inc. |
Methods of treating substance abuse
|
|
US20210267966A1
(en)
|
2018-06-21 |
2021-09-02 |
Robert Joseph Petcavich |
Method of Inducing Dendritic and Synaptic Genesis in Neurodegenerative Chronic Diseases
|
|
WO2020024060A1
(en)
|
2018-08-01 |
2020-02-06 |
Mcmaster University |
Methods for inhibiting microbe growth
|
|
WO2020041329A1
(en)
|
2018-08-20 |
2020-02-27 |
Yale University |
Combination therapy for treating or preventing depression or other mood diseases
|
|
WO2020053196A1
(en)
|
2018-09-10 |
2020-03-19 |
Universität Basel |
Method for the biocatalytic alkylation of a substrate
|
|
CA3125439A1
(en)
|
2019-01-04 |
2020-07-09 |
Apollo Neuroscience, Inc. |
Systems and methods of wave generation for transcutaneous vibration
|
|
BR112021014750A2
(pt)
|
2019-01-30 |
2021-09-28 |
Diamond Therapeutics Inc. |
Composições e métodos para gerenciar transtornos
|
|
KR20220009955A
(ko)
|
2019-04-17 |
2022-01-25 |
컴퍼스 패쓰파인더 리미티드 |
실로시빈에 의한 우울증 및 기타 다양한 장애의 치료
|
|
US11766445B2
(en)
|
2019-07-18 |
2023-09-26 |
Concept Matrix Solutions |
Oral soft gel capsule containing psychedelic compound
|
|
EP4009026A1
(en)
|
2020-12-02 |
2022-06-08 |
Volvo Truck Corporation |
An air-actuated vehicle system and a method of detecting leakage in an air-actuated vehicle system
|
|
WO2022207746A1
(en)
|
2021-03-30 |
2022-10-06 |
Compass Pathfinder Limited |
Psilocybin compositions, methods of making and methods of using the same
|